Adding CX-4945 to bortezomib treatment resulted in UPR pathway inhibition through deletion of pro-survival ER chaperon BIP/Grp78 and, only in B-ALL models, the combination released the NF-κB pro-apoptotic ability. This evidence concerns the gene NFKB1 and precursor B-cell acute lymphoblastic leukemia.